drugset / Trial / NCT02706678

Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients

NCT02706678 ↗

Phase 4 Completed 105 enrolled Astellas Pharma Inc
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the effects of tacrolimus sustained-release capsules replacing cyclosporin on kidney function of renal transplant recipients.

Timeline

Start
2010-12-29
Primary completion
2012-08-01
Completion
2012-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule — Oral